Nalaganje...
Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
Immunotherapy has changed the paradigm of cancer treatments. In this way, several combinatorial strategies based on monoclonal antibodies (mAb) such as anti (a)-PD-1 or anti (a)-PD-L1 are often reported to yield promising clinical benefits. However, the pharmacokinetic (PK) behavior of these mAbs is...
Shranjeno v:
| izdano v: | Pharmaceutics |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356959/ https://ncbi.nlm.nih.gov/pubmed/32604843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12060595 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|